Skip to main content
. 2020 Feb 20;106(1):154–162. doi: 10.3324/haematol.2019.237719

Figure 4.

Figure 4.

Longitudinal assessment of mutation abundance in plasma circulating tumor DNA upon treatment. Evolution of median circulating tumor DNA (ctDNA) variant allelic frequency (VAF) for each patient (with detectable ctDNA mutation at diagnosis) throughout treatment (at diagnosis [“diag”] n=41) and after two cycles (C2) of chemotherapy (“post C2”, n=31). UPN: universal patient identification number.